Filed with ASX · · 3 pages · English
Actinogen Medical Limited has announced the achievement of a database lock for its XanaMIA pivotal Alzheimer’s disease trial, confirming that topline results are now expected in mid-November. The database lock signifies that the trial data is finalized and ready for statistical analysis, which will produce the final results. Dr. Steven Gourlay, CEO, expressed optimism about the potential of Xanamem as a treatment option for Alzheimer’s patients.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
ASX ANNOUNCEMENT Actinogen XanaMIA pivotal Alzheimer’s disease trial achieves database lock, confirming topline results now expected mid-November Sydney, 21 October 2026. Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that following formal achievement of its...
Actinogen Medical Limited on 6ix
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical